{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T05:00:19Z","timestamp":1795064419250,"version":"4.10.2"},"reference-count":46,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1136\/annrheumdis-2011-200908","type":"journal-article","created":{"date-parts":[[2012,5,15]],"date-time":"2012-05-15T00:38:25Z","timestamp":1337042305000},"page":"1839-1848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":322,"title":["Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions"],"prefix":"10.1016","volume":"71","author":[{"given":"Naomi","family":"Schlesinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieke E","family":"Alten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Bardin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H Ralph","family":"Schumacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Gimona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valda","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander K","family":"So","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2011-200908_bib1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S0140-6736(09)60883-7","article-title":"Gout.","volume":"375","author":"Richette","year":"2010","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2011-200908_bib2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/ajkd.2002.33911","article-title":"The association between gout and nephrolithiasis: the National Health and Nutrition Examination Survey III, 1988\u20131994.","volume":"40","author":"Kramer","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1136\/annrheumdis-2011-200908_bib3","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/ar2509","article-title":"Developments in the scientific and clinical understanding of gout.","volume":"10","author":"So","year":"2008","journal-title":"Arthritis Res Ther"},{"issue":"15 Suppl","key":"10.1136\/annrheumdis-2011-200908_bib4","first-page":"S443","article-title":"Diagnosis of gout: clinical, laboratory, and radiologic findings.","volume":"11","author":"Schlesinger","year":"2005","journal-title":"Am J Manag Care"},{"key":"10.1136\/annrheumdis-2011-200908_bib5","first-page":"759","article-title":"Diagnosis of gout.","volume":"98","author":"Schlesinger","year":"2007","journal-title":"Minerva Med"},{"key":"10.1136\/annrheumdis-2011-200908_bib6","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome.","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"key":"10.1136\/annrheumdis-2011-200908_bib7","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1093\/rheumatology\/kem056a","article-title":"British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout.","volume":"46","author":"Jordan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2011-200908_bib8","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/ard.2006.055269","article-title":"EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).","volume":"65","author":"Zhang","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-200908_bib9","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMcp1001124","article-title":"Clinical practice. Gout.","volume":"364","author":"Neogi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2011-200908_bib10","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/ar2659","article-title":"Adherence with urate-lowering therapies for the treatment of gout.","volume":"11","author":"Harrold","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2011-200908_bib11","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/01.rhu.0000147049.12220.32","article-title":"Prevalence of Comorbid Conditions and Prescription Medication Use Among Patients With Gout and Hyperuricemia in a Managed Care Setting.","volume":"10","author":"Riedel","year":"2004","journal-title":"J Clin Rheumatol"},{"key":"10.1136\/annrheumdis-2011-200908_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.amjmed.2010.09.012","article-title":"Prevalence of contraindications and prescription of pharmacologic therapies for gout.","volume":"124","author":"Keenan","year":"2011","journal-title":"Am J Med"},{"key":"10.1136\/annrheumdis-2011-200908_bib13","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1136\/ard.2010.128454","article-title":"The pathogenesis of bone erosions in gouty arthritis.","volume":"69","author":"Schlesinger","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-200908_bib14","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.3899\/jrheum.071229","article-title":"Quality of life and disability in patients with treatment-failure gout.","volume":"36","author":"Becker","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2011-200908_bib15","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/rheumatology\/kep047","article-title":"Perceptions of disease and health-related quality of life among patients with gout.","volume":"48","author":"Lee","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2011-200908_bib16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s11926-010-0084-3","article-title":"Gout, hyperuricemia, and the risk of cardiovascular disease: cause and effect?","volume":"12","author":"Shah","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1136\/annrheumdis-2011-200908_bib17","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.2165\/00003495-200464210-00003","article-title":"Management of acute and chronic gouty arthritis: present state-of-the-art.","volume":"64","author":"Schlesinger","year":"2004","journal-title":"Drugs"},{"key":"10.1136\/annrheumdis-2011-200908_bib18","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/ar2952","article-title":"Mechanisms of inflammation in gout.","volume":"12","author":"Busso","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2011-200908_bib19","doi-asserted-by":"crossref","first-page":"R67","DOI":"10.1186\/ar2438","article-title":"The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis.","volume":"10","author":"Alten","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/annrheumdis-2011-200908_bib20","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1002\/art.27600","article-title":"Canakinumab for the treatment of acute flares in difficult-to-treat gouty arthritis: results of a multicenter, phase II, dose-ranging study.","volume":"62","author":"So","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-200908_bib21","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/art.1780200320","article-title":"Preliminary criteria for the classification of the acute arthritis of primary gout.","volume":"20","author":"Wallace","year":"1977","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-200908_bib22","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa0810787","article-title":"Use of canakinumab in the cryopyrin-associated periodic syndrome.","volume":"360","author":"Lachmann","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2011-200908_bib23","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1136\/ard.2009.108936","article-title":"The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study.","volume":"68","author":"Terkeltaub","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-200908_bib24","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1002\/art.27635","article-title":"Interleukin-1 antagonism in acute gout: is targeting a single cytokine the answer?","volume":"62","author":"Neogi","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-200908_bib25","doi-asserted-by":"crossref","first-page":"R28","DOI":"10.1186\/ar2143","article-title":"A pilot study of IL-1 inhibition by anakinra in acute gout.","volume":"9","author":"So","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 10","key":"10.1136\/annrheumdis-2011-200908_bib26","first-page":"S69","article-title":"The safety and efficacy of anakinra in the treatment of acute gout in hospitalized patients","volume":"62","author":"Cho","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-200908_bib27","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","article-title":"Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial.","volume":"371","author":"Janssens","year":"2008","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2011-200908_bib28","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1136\/ard.2010.144063","article-title":"Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study.","volume":"70","author":"Schlesinger","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-200908_bib29","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1006\/cyto.2001.0974","article-title":"C-reactive protein levels are influenced by common IL-1 gene variations.","volume":"17","author":"Berger","year":"2002","journal-title":"Cytokine"},{"key":"10.1136\/annrheumdis-2011-200908_bib30","unstructured":"Ilaris (canakinumab) injection (package insert). East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2009."},{"key":"10.1136\/annrheumdis-2011-200908_bib31","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nri3010","article-title":"Immunity against Staphylococcus aureus cutaneous infections.","volume":"11","author":"Miller","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1136\/annrheumdis-2011-200908_bib32","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1128\/CMR.00001-11","article-title":"Infectious diseases in patients with IRAK-4, MyD88, NEMO, or I\u03baB\u03b1 deficiency.","volume":"24","author":"Picard","year":"2011","journal-title":"Clin Microbiol Rev"},{"key":"10.1136\/annrheumdis-2011-200908_bib33","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1471-2474-12-153","article-title":"Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study.","volume":"12","author":"Alten","year":"2011","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1136\/annrheumdis-2011-200908_bib34","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard.56.11.696a","article-title":"Serum uric acid in acute gout.","volume":"56","author":"Logan","year":"1997","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-200908_bib35","first-page":"1950","article-title":"The inflammatory process in the mechanism of decreased serum uric acid concentrations during acute gouty arthritis.","volume":"29","author":"Urano","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2011-200908_bib36","first-page":"2265","article-title":"Serum urate during bouts of acute gouty arthritis.","volume":"24","author":"Schlesinger","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2011-200908_bib37","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3899\/jrheum.080938","article-title":"Serum urate during acute gout.","volume":"36","author":"Schlesinger","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1136\/annrheumdis-2011-200908_bib38","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1136\/ard.2007.071530","article-title":"International survey on the diagnosis and management of gout.","volume":"66","author":"Doherty","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-200908_bib39","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/ard.2007.078469","article-title":"Why is gout so poorly managed?","volume":"66","author":"Pascual","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2011-200908_bib40","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1136\/bmj.324.7352.1488","article-title":"Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.","volume":"324","author":"Schumacher","year":"2002","journal-title":"BMJ"},{"key":"10.1136\/annrheumdis-2011-200908_bib41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S0149-2918(04)90035-5","article-title":"A single-blind, randomized, controlled trial to assess the efficacy and tolerability of rofecoxib, diclofenac sodium, and meloxicam in patients with acute gouty arthritis.","volume":"26","author":"Cheng","year":"2004","journal-title":"Clin Ther"},{"key":"10.1136\/annrheumdis-2011-200908_bib42","unstructured":"Kenalog-40 (triamcinolone acetonide) injectable suspension (for intramuscular or intra-articular use only) (package insert). Princeton, NJ: Bristol-Myers Squibb Company, 2011."},{"key":"10.1136\/annrheumdis-2011-200908_bib43","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/art.20007","article-title":"Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.","volume":"50","author":"Rubin","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1136\/annrheumdis-2011-200908_bib44","author":"Pfizer","year":"2011","journal-title":"Celebrex in acute gouty arthritis study"},{"key":"10.1136\/annrheumdis-2011-200908_bib45","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/rheumatology\/kem090","article-title":"Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.","volume":"46","author":"Willburger","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/annrheumdis-2011-200908_bib46","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study.","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724186359?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724186359?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2011-200908","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,5]],"date-time":"2025-01-05T08:40:17Z","timestamp":1736066417000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724186359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":46,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S0003496724186359"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2011-200908","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.716597950.792003000","asserted-by":"object"}]},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2011-200908","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}